GleamWall
中文EN

GALT GALECTIN THERAPEUTICS INC

Pharmaceutical Preparations · Nasdaq · SEC CIK 1133416 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY37.8%
TTM EPS YoY45.8%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE—
ROA-179.3%
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets357.0%
Debt / equity—
Current ratio0.28x
Interest coverage-2.20x

Cash quality & payout

Operating cash flow / net income0.63x
Accruals ratio-66.3%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue——
R&D expense$14.29M$36.57M
SG&A expense$5.79M$5.86M
Operating income-$20.09M-$42.43M
Interest expense$7.33M$5.54M
Income tax$0$0
Net income-$30.84M-$47.05M
EBITDA—-$42.43M
EPS (basic)-0.48-0.76
EPS (diluted)-0.48-0.76
Weighted avg. shares (diluted)63.90M62.31M
Balance sheet
Cash & equivalents$17.72M$15.12M
Current assets$19.44M$17.25M
PP&E, net$0$0
Total assets$19.53M$17.50M
Current liabilities$8.03M$35.41M
Total liabilities$145.73M$120.56M
Shareholders' equity-$127.92M-$104.79M
Shares outstanding65.20M63.16M
Cash flow statement
Operating cash flow-$23.88M-$41.77M
Investing cash flow$0$0
Financing cash flow$26.48M$31.23M
Depreciation & amortization—$0
Stock-based compensation$1.66M$2.45M

Free plan shows the latest 2 periods; Pro shows all 16 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.